Wire
Drug makers could lose more Medicare deals by walking away
If a primary manufacturer walks away from Medicare price talks, the proposal would bar it from later program agreements and the discount program for the rest of that drug’s pricing period.
A drug maker that walks away from Medicare’s price talks would lose more than one shot at a deal. Under the federal proposal, the manufacturer could not join later program agreements or the Manufacturer Discount Program for the rest of that drug’s pricing period.
The same exit condition would also keep that manufacturer from seeking coverage for any of its drugs under the Manufacturer Discount Program, a separate federal discount arrangement. That makes leaving the negotiation program look less like a single decision about one medicine and more like a broader cutoff.
A wider price window
The practical effect is leverage. A manufacturer that backs out would be accepting a lockout that lasts for the full price period on the selected drug, not just a temporary pause while negotiations cool off. The proposal treats that lockout as part of the exit itself.
That matters because the consequences reach beyond the one drug at the center of the talks. For manufacturers, the choice to leave would ripple into other federal drug arrangements. For Medicare, the rule would make the negotiation program harder to treat as optional.